HeartBeam Inc. (NASDAQ: BEAT) announced the closing of its underwritten public offering of 12.5 million shares of common stock, generating gross proceeds of $10 million before expenses. The transaction, completed on April 16, 2026, included participation from key stakeholders such as ClearCardio, company leadership, and institutional investors. The funds are earmarked to accelerate the commercialization of HeartBeam’s FDA-cleared 12-lead synthesized ECG system, further development of its extended-wear patch and heart attack detection technologies, expansion of artificial intelligence capabilities, and general corporate purposes.
The company’s technology represents a significant advancement in cardiac monitoring. HeartBeam is developing the first cable-free device capable of collecting ECG signals in 3D from three non-coplanar directions and synthesizing them into a 12-lead ECG. This platform is designed for portable use, enabling patients to receive actionable heart intelligence outside traditional medical facilities. The FDA clearance for arrhythmia assessment was obtained in December 2024, followed by clearance for the 12-lead ECG synthesis software in December 2025. HeartBeam holds over 20 issued patents related to its technology.
The successful capital raise underscores investor confidence in HeartBeam’s potential to transform cardiac care. By enabling remote monitoring and early detection of cardiac conditions, the technology could reduce hospital visits and improve patient outcomes. The funding will support scaling manufacturing, expanding sales and marketing efforts, and advancing clinical studies for heart attack detection. Additionally, the company plans to enhance its AI algorithms to improve diagnostic accuracy.
For more details on the offering, visit the full press release at https://ibn.fm/9iNYY. Information on the cleared indications for use can be found at https://www.heartbeam.com/indications.
The latest news and updates on HeartBeam are available in the company’s newsroom at https://ibn.fm/BEAT.
